Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 1101 | Apheresis | Allogeneic | B-cell Precursor Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Slovakia | 67 |
| 1102 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 72 |
| 1103 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 52 |
| 1104 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belgium | 64 |
| 1105 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2025 | Standard Therapy | Italy | 68 |
| 1106 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Canada | 56 |
| 1107 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 64 |
| 1108 | Apheresis | Allogeneic | Other Myelofibrosis/Myelosclerosis | Hematology | 2025 | Standard Therapy | USA | 55 |
| 1109 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 64 |
| 1110 | Apheresis | Allogeneic | Myelodysplastic disorder | Hematology | 2025 | Standard Therapy | France | 63 |
| 1111 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 1112 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 20 |
| 1113 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 23 |
| 1114 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 73 |
| 1115 | Apheresis | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 9 |
| 1116 | Apheresis | Allogeneic | Lymphoma – DLBCL | Hematology | 2025 | Standard Therapy | United Kingdom | 55 |
| 1117 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1118 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 58 |
| 1119 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 73 |
| 1120 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 35 |
| 1121 | Apheresis | Allogeneic | Chronic myelomonocytic leukemia | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1122 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1123 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 1124 | Apheresis | Autologous | Diffuse large B-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 42 |
| 1125 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Netherlands | 65 |
| 1126 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 60 |
| 1127 | Apheresis | Allogeneic | Post Mielofibrosis | Hematology | 2025 | Standard Therapy | Poland | 66 |
| 1128 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1129 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 17 |
| 1130 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | USA | 72 |
| 1131 | Apheresis | Allogeneic | T-cell prolymphocytic leukemia | Hematology | 2025 | Standard Therapy | New Zealand | 64 |
| 1132 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1133 | Apheresis | Allogeneic | Mielofibrosis | Hematology | 2025 | Standard Therapy | Finland | 68 |
| 1134 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 35 |
| 1135 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 34 |
| 1136 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belgium | 63 |
| 1137 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 72 |
| 1138 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Switzerland | 69 |
| 1139 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 52 |
| 1140 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 26 |
| 1141 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1142 | Apheresis | Allogeneic | Chronic Lymphocyte Leukemia | Hematology | 2025 | Standard Therapy | Poland | 71 |
| 1143 | Apheresis | Allogeneic | Anaplastic Large Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 3 |
| 1144 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | USA | 71 |
| 1145 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 29 |
| 1146 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 38 |
| 1147 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 28 |
| 1148 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 46 |
| 1149 | Apheresis | Allogeneic | Hodking lymphoma | Hematology | 2025 | Standard Therapy | Spain | 28 |
| 1150 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Slovakia | 52 |
| 1151 | Apheresis | Allogeneic | T-NHL Angioimmunoblastic T-cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 1152 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 71 |
| 1153 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 23 |
| 1154 | Apheresis | Allogeneic | Mielodysplastic syndrome | Hematology | 2025 | Standard Therapy | Spain | 69 |
| 1155 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Brazil | 71 |
| 1156 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 36 |
| 1157 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 1158 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1159 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 61 |
| 1160 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 35 |
| 1161 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 39 |
| 1162 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Serbia | 58 |
| 1163 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | USA | 47 |
| 1164 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Netherlands | 62 |
| 1165 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 1166 | Apheresis | Allogeneic | T-cell Lymphoma | Hematology | 2025 | Standard Therapy | United Kingdom | 35 |
| 1167 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 71 |
| 1168 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1169 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1170 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 71 |
| 1171 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 39 |
| 1172 | Apheresis | Autologous | Primary central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1173 | Apheresis | Allogeneic | Myelodysplastic syndrome | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 1174 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1175 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1176 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1177 | Apheresis | Autologous | Hodgkin lymphoma | Hematology | 2025 | Standard Therapy | Germany | 32 |
| 1178 | Apheresis | Allogeneic | Myelodysplastic syndrome | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1179 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 1180 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Columbia | 62 |
| 1181 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 46 |
| 1182 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 66 |
| 1183 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 46 |
| 1184 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 33 |
| 1185 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 31 |
| 1186 | Apheresis | Allogeneic | B-Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1187 | Apheresis | Allogeneic | B-Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 62 |
| 1188 | Apheresis | Allogeneic | Hemophagocytic lymphohistiocytosis | Hematology | 2025 | Standard Therapy | Czechia | 27 |
| 1189 | Apheresis | Allogeneic | Shwachman-Diamond Syndrome | Hematology | 2025 | Standard Therapy | Spain | 11 |
| 1190 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 67 |
| 1191 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Canada | 60 |
| 1192 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | CROATIA | 43 |
| 1193 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 1194 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Austria | 61 |
| 1195 | Apheresis | Allogeneic | Other Immune System | Hematology | 2025 | Standard Therapy | USA | 62 |
| 1196 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1197 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 63 |
| 1198 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 66 |
| 1199 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Denmark | 50 |
| 1200 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 62 |